<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535573</url>
  </required_header>
  <id_info>
    <org_study_id>2P50DA009262-16A1</org_study_id>
    <nct_id>NCT01535573</nct_id>
  </id_info>
  <brief_title>Citalopram for Cocaine Dependence</brief_title>
  <official_title>Clinical Trial of Serotonin Medication Combination in Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joy Schmitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine
      dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent
      patients will be assigned equally to one of three medication conditions: placebo or the
      Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or
      40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase
      periods of sustained abstinence substantially more than placebo. Performance on a set of
      behavioral tasks of impulsivity will be analyzed as potential predictors of treatment
      response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abstinence</measure>
    <time_frame>over 9 weeks of treatment</time_frame>
    <description>The proportion of subjects in each treatment group who are cocaine abstinent during the last 2 weeks of the Treatment Phase (weeks 8-9).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cocaine Use Days</measure>
    <time_frame>over 9 weeks of treatment</time_frame>
    <description>Weekly fraction of cocaine use days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine-negative Urines</measure>
    <time_frame>over 9 weeks of treatment</time_frame>
    <description>Percent negative urines collected during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in Treatment</measure>
    <time_frame>over 9 weeks of treatment</time_frame>
    <description>Proportion of subjects remaining in treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Citalopram low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Citalopram 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citalopram high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Citalopram 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>20 mg once per day for 9 weeks</description>
    <arm_group_label>Citalopram low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>40 mg per day for 9 weeks</description>
    <arm_group_label>Citalopram high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg per day for 9 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18 and 60 years of age

          -  meet Diagnostic and Statistical Manual 4 (DSM-IV) criteria for current cocaine
             dependence

          -  be in acceptable health on the basis of interview, medical history and physical exam

          -  able to provide the names of at least 2 persons who can generally locate their
             whereabouts.

        Exclusion Criteria:

          -  diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or
             nicotine

          -  have a psychiatric disorder or neurological disease or disorder requiring ongoing
             treatment and/or making study participation unsafe

          -  medical conditions contraindicating citalopram pharmacotherapy

          -  taking medications known to have significant drug interactions with the study
             medication

          -  pregnant or nursing for female patients

          -  having plans to leave the immediate geographical area within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy M Schmitz, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT-Houston Behavioral and Biomedical Sciences Building</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joy Schmitz</investigator_full_name>
    <investigator_title>Professor , Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>citalopram</keyword>
  <keyword>treatment</keyword>
  <keyword>serotonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

